CUTIA-B: CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESSIN HONG KONG
CUTIA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
CUTIA-B: VOLUNTARY ANNOUNCEMENT - COMPLETION OF PHASE II CLINICAL TRIAL OF CU-20401(RECOMBINANT MUTANT COLLAGENASE) FORSUBMENTAL ADIPOSE ACCUMULATION IN CHINA
CUTIA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
CUTIA-B: VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANTCOLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION REACHED PRIMARY ENDPOINT
CUTIA-B: VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OFCU-40102 (TOPICAL FINASTERIDE SPRAY) AND CU-30101(LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM)IN CHINA WERE PRESENTED AT THE 19TH CDA ANNUAL MEETING
CUTIA-B: VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDINGBY THE CHIEF EXECUTIVE OFFICERAND EXECUTIVE DIRECTOR
CUTIA-B: VOLUNTARY ANNOUNCEMENT -CU-10201 (TOPICAL 4% MINOCYCLINE FOAM)OBTAINED MARKETING APPROVAL BY THE NATIONALMEDICAL PRODUCTS ADMINISTRATION
CUTIA-B: VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDINGBY THE CHIEF EXECUTIVE OFFICERAND EXECUTIVE DIRECTOR
CUTIA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
CUTIA-B: OPERATIONAL UPDATE FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024
CUTIA-B: Next Day Disclosure Return
CUTIA-B: VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF CU-20401(RECOMBINANT MUTANT COLLAGENASE) FORSUBMENTAL ADIPOSE ACCUMULATIONCOMPLETED DATABASE LOCK
CUTIA-B: Next Day Disclosure Return
CUTIA-B: Next Day Disclosure Return
CUTIA-B: Next Day Disclosure Return
CUTIA-B: VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR
CUTIA-B: Next Day Disclosure Return
CUTIA-B: Next Day Disclosure Return
CUTIA-B: VOLUNTARY ANNOUNCEMENT -INCREASE IN SHAREHOLDING BY THE CHIEF EXECUTIVE OFFICERAND EXECUTIVE DIRECTOR